Maplight Therapeutics’ once-daily schizophrenia program disappointed investors after Phase 2 results failed to meet the primary endpoint, despite positive overall safety and efficacy signals under a twice-daily regimen. The company said the twice-daily dose achieved a prespecified measure of symptom improvement, while the once-daily arm did not. The mixed readout triggered a sharp drop in the stock, reflecting market sensitivity to dosing regimens that could compete against established products. Maplight also signaled continued analysis for whether a path forward exists for the less responsive once-daily approach. The episode underscores how schedule and persistence effects can determine commercial viability in central nervous system drug development, particularly when near-term comparators are already labeled.